Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.

A polycyclic aromatic compound or a condensed multimer thereof, according to the present invention, is employed in an organic layer in an organoelectroluminescent device, thereby enabling the implementation of an organoelectroluminescent device having high efficiency and a long lifespan, and thus the present invention may be industrially useful in various display devices such as a flat panel display device, a flexible display device, a monochromatic or white flat panel lighting device, and a monochromatic or white flexible lighting device.

The present invention relates to: an anthracene derivative compound having a specific structure; and an organic light-emitting device having low-voltage driving characteristics, comprising same, and also relates to an organic light-emitting device, which employs, as a dopant compound, a polycyclic aromatic derivative compound having a specific structure together in a light-emitting layer, and thus has excellent light-emitting characteristics such as further improved low-voltage driving.

A method of producing a radiofluorinated compound comprising the steps of forming a reaction mixture comprising a reactant having a formula of R—Y and a radiofluorinating agent having a formula of R′—.sup.18F; and contacting the reaction mixture with microwave radiation to achieve a temperature of between 100° C. and 250° C. for a time sufficient to convert at least 10% of the reactant into the radiofluorinated compound having a formula of R—.sup.18F, wherein R is selected from the group consisting of an alkyl (C.sub.1-C.sub.20), a cycloalkyl (C.sub.3-C.sub.10), an aryl, a heteroaryl, an aralkyl and an alkenyl group (C.sub.2-C.sub.20); Y is selected from the group consisting of a sulfonate, a nitro, an acetate and a halogen; and R′ is selected from the group consisting of an alkali metal cation, an alkaline earth metal cation, a transition metal cation, an ammonium cation, and a tetraalkylammonium cation is provided.

The present invention relates to methods for labeling a PSMA binding ligand with a radioactive isotope, preferably .sup.68Ga, .sup.67Ga or .sup.64Cu, said method comprising the steps of: i. providing a single vial comprising, in dried form, said PSMA binding ligand f the following formula (I): (I) at least one buffering agent, sodium chloride and a stabilizer against radiolytic degradation, ii. adding a solution of said radioactive isotope into said single vial, thereby obtaining a solution of said PSMA binding ligand of formula (I) with said radioactive isotope, iii. mixing the solution obtained in ii., and incubating it for a sufficient period of time for obtaining said PSMA binding ligand labelled with said radioactive isotope, and, iv. optionally, adjusting the pH of the solution.

##STR00001##

The present invention refers to a process for the trans-selective hydroboration of internal alkynes and the so-obtained products. The inventive process makes use of a borane of the formula X.sup.1X.sup.2BH selected from the group of dialkyl boranes or di(alkoxy)boranes which are reacted with the internal alkynes in the presence of a cyclyopentadienyl-coordinated ruthenium catalyst.

Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid tumors, have the formula:

##STR00001##

R.sub.1 includes a chelating agent that is chelated to a metal atom, wherein the metal atom is a positron or single photon emitting metal isotope with a half life of greater than or equal to 4 hours, or an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R.sub.2 is —N.sup.+H.sub.3, —N.sup.+H.sub.2Z, —N.sup.+HZ.sub.2, or —N.sup.+Z.sub.3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2.

Provided are organometallic compounds. Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

An organometallic compound represented by Formula 1, a light-emitting device including the same, and an electronic apparatus including the light-emitting device are disclosed. In Formula 1, the substituents are as described in more detail in the specification.

##STR00001##

Disclosed is a compound of formula (I):

##STR00001##

wherein L, R.sup.1-R.sup.5, A, B, M, and n are as defined in the specification, as well as a method of preparing the compound. Also disclosed are a method of blood-pool imaging in a mammal and a method of imaging a lymph node in a mammal, comprising use of the compound.